Utah Medical Products
UTMD
112 hedge funds and large institutions have $123M invested in Utah Medical Products in 2025 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 38 increasing their positions, 39 reducing their positions, and 14 closing their positions.
21% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 14
3% more funds holding
Funds holding: 109 → 112 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less capital invested
Capital invested by funds: $126M → $123M (-$2.66M)
3% less repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 39
1.82% less ownership
Funds ownership: 68.29% → 66.47% (-1.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$1.75M |
| 2 |
BIP
Brandes Investment Partners
La Jolla,
California
|
+$1.58M |
| 3 |
BlackRock
New York
|
+$1.03M |
| 4 |
HCM
Huber Capital Management
El Segundo,
California
|
+$845K |
| 5 |
QCM
Quantinno Capital Management
New York
|
+$581K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$3.6M |
| 2 |
RA
Royce & Associates
New York
|
-$2.35M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$899K |
| 4 |
Two Sigma Investments
New York
|
-$739K |
| 5 |
Allspring Global Investments
Charlotte,
North Carolina
|
-$735K |
UTMD Hedge Fund Activity: Q2 2025 in Review
112 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Utah Medical Products (UTMD) for Q2 2025, worth a combined $123M — down 2.1% from $126M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new UTMD positions and 14 closed out — a net gain of 3 holders — while 38 added to existing stakes and 39 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $1.75M. The largest seller was JP Morgan Chase, cutting an estimated $3.6M.
- 112 institutional investors held Utah Medical Products (UTMD) as of Q2 2025, up from 109 in Q1 2025.
- Funds reported $123M of Utah Medical Products stock for Q2 2025, down 2.1% quarter-over-quarter.
- 17 funds opened new Utah Medical Products positions in Q2 2025 and 14 closed out, a net change of +3 holders.
- The largest Utah Medical Products buyer in Q2 2025 was Morgan Stanley, an estimated $1.75M added.
- The largest Utah Medical Products seller in Q2 2025 was JP Morgan Chase, an estimated $3.6M sold.
Based on aggregated 13F filings for Q2 2025.